Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer.
A total of 7 patients with clinical stage C prostate cancer determined by digital rectal examination, transrectal ultrasonography, radionuclide bone scanning and serum prostatic acid phosphatase determination was treated with luteinizing hormone-releasing hormone analogues for 2 to 5 months in an attempt to downstage the disease. Although substantial decreases in prostate specific antigen level and prostatic volume occurred, only 2 patients experienced pathological downstaging of disease. We conclude that luteinizing hormone-releasing hormone therapy for downstaging of clinical stage C prostatic cancer is of limited value.
T J
TJ
Kennedy
A M
AM
Sonneland
M M
MM
Marlett
R H
RH
Troup
D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone; D017430:Prostate-Specific Antigen